Similarly, a prospective real-life study of 46 French patients with AD revealed that DAOSD was associated with IgE serum level >1,000 IU/mL at the initiation of dupilumab treatment (OR: 10.6, 95% CI: 1.2–91.3) (Touhouche et al., 2021). The gene discussed is IGHE; the disease is Alzheimer disease.